Combination Intensity-Modulated Radiotherapy and Sorafenib Improves Outcomes in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis.

J Oncol · 2021 · PMC8664501 · PMID 34899910

Europe PMC DOI

hedged sentences

0.0360

closest p · 0.7× alpha

0.0360

boldest claim

The sentences

a favorable trendP =0.036actually significant

Compared with group B (IMRT alone), group A (IMRT plus sorafenib) displayed a favorable trend in median OS (11.0 versus 9.0 months, P =0.036), 1 yr and 2 yrs OS (44.9% versus 28.6% and 3.8% versus 2.6%), median PFS (6.0 versus 3.0 months, P =0.012), 1 yr and 2 yrs PFS (20.7% versus 2.7% and 6.9% versus 0.0%).

also in 1,335 other papers

did not reach statistical significanceno p-value reported

[ 22 ] evaluated the efficacy of SBRT with and/or without sorafenib for advanced HCC with PVTT and found that SBRT combined with sorafenib improved response rate (77.77% versus 75.00% for SBRT only), median PFS (6.0 versus 3.0 months for SBRT only), median OS (12.5 versus 7.0 months for SBRT only), and OS, albeit the trends did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.